Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study

@article{Ohta2015QualityOL,
  title={Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study},
  author={Hiroaki Ohta and Etsuro Hamaya and Masanori Taketsuna and Hideaki Sowa},
  journal={Current Medical Research and Opinion},
  year={2015},
  volume={31},
  pages={85 - 94}
}
Abstract Objectives: To assess the effect of active vitamin D3 on quality of life (QOL) and pain in raloxifene-treated Japanese women with postmenopausal osteoporosis. Research design and methods: This is a post hoc analysis of a previous prospective postmarketing observational study conducted without a comparator group. This study was conducted in 60 Japanese hospitals from September 2007 to February 2009. We compared changes from baseline in QOL and pain in patients receiving raloxifene plus… 
Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
TLDR
Combination therapy with raloxifene and cholecalciferol significantly improves quality of life with no serious adverse events and high patient satisfaction at 6 months of treatment, and real-world data suggest that this regimen is a promising option for postmenopausal women with low bone mass.
A Combination Treatment of Raloxifene and Vitamin D Enhances Bone-to-Tendon Healing of the Rotator Cuff in a Rat Model
TLDR
The combination treatment of RLX and vitamin D prevented a decrease in local BMD (greater tuberosity of the proximal humerus) and enhanced tendon-to-bone healing of the rotator cuff in a rat model.

References

SHOWING 1-10 OF 61 REFERENCES
Quality of life in raloxifene-treated Japanese women with postmenopausal osteoporosis: a prospective, postmarketing observational study
TLDR
It is suggested that standard treatment with raloxifene improves QOL and relieves pain in Japanese women with postmenopausal osteoporosis in a real-world clinical setting.
Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration
TLDR
Raloxifene treatment in postmenopausal women with osteoporosis was associated with a marked reduction of skeletal pain and analgesic consumption and an improvement in subjective sleep quality.
Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis.
TLDR
Osteoporosis therapies that prevent the development of back pain in postmenopausal women may also prevent decreases in HRQOL.
Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial
TLDR
It is demonstrated that raloxifene is associated with early increases in lumbar spine BMD, has favorable effects on biochemical markers of bone turnover and lipid profile, and is well tolerated in postmenopausal Japanese women.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
TLDR
In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture and was associated with a lower incidence of breast cancer.
Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis
TLDR
Raloxifene treatment at 60 mg/day for 1 year resulted in a significant reduction in the risk of new clinical vertebral fractures and any new clinical fracture in postmenopausal Asian women with osteoporosis.
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
TLDR
Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis.
Validation of the Japanese Osteoporosis Quality of Life Questionnaire
TLDR
The reliability and the validity of the revised Japanese Osteoporosis Quality of Life Questionnaire (JOQOL) were demonstrated and it was concluded that the high reliability of JOQOL was demonstrated.
Vitamin D status and response to treatment in post-menopausal osteoporosis
TLDR
Optimal vitamin D repletion seems to be necessary to maximize the response to anti-resorbers in terms of both BMD changes and anti-fracture efficacy.
...
...